Evidence map›Paper›PMID 41535728›Full record

ArticleCurrent neuropharmacology2025

Corrigendum to: Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review.

Reyna Lamas-Aguilar, Araceli Diaz-Ruiz, Luz Navarro, Raúl Miranda-Ojeda, María de Los Ángeles Martínez-Cárdenas, Alfonso Mata-Bermudez, Camilo Rios

Abstract readPublished Erratum
In one paragraph

Article in Current neuropharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Reyna Lamas-AguilarDepartamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Ciudad de México, México.
Araceli Diaz-RuizDepartamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Ciudad de México, México.
Luz NavarroDepartamento de Fisiología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.
Raúl Miranda-OjedaThe Mind Project, Office for Equity, Diversity, Inclusion, and Belonging, Harvard University, Smith Campus Center, Cambridge, Massachusetts, USA.
María de Los Ángeles Martínez-CárdenasDepartamento de Atención a la Salud, Universidad Autónoma Metropolitana Unidad Xochimilco, Ciudad de México, México.
Alfonso Mata-BermudezDepartamento de Atención a la Salud, Universidad Autónoma Metropolitana Unidad Xochimilco, Ciudad de México, México.
Camilo RiosDirección de Investigación, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra., Ciudad de México, México.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The author has identified an error in the department of the authors in the article titled, Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review", published in Current Neuropharmacology, 2024, 22(11), 1899-1908 [1]. Details of the error and a correction are provided here. ORIGINAL RAÚL MIRANDA-OJEDA

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsModafinilAdultAnimalsHumansCentral Nervous System StimulantsModafinil

Identifiers

PMID41535728
PMCPMC12676043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.